(Total Views: 574)
Posted On: 04/14/2019 7:57:18 PM
Post# of 15624
I agree with you on the basis of preclinical work, but to my knowledge to date, the products haven't been tried with people who have the diseases the company is going after. Had the Phase 1 for the psoriasis cream been done with people who had psoriasis, it would be a different story, but it wasn't.
I'm hoping the planned Phase 1 for the sublingual tablet will be done with people who have conditions that should benefit from it. I know a Phase 2 is planned for the psoriasis cream, and that should tell a lot. I know we've already done more than a lot of companies selling products have.
The reason I've stressed the fact that planned trials should be put in the clinical trials database is because it would answer practically all questions about the trials. It may take some additional effort to do it, but I suspect that virtually everything that's revealed in the clinical trials database can be found in what's done with the IRB as the trial's being designed. I'm of the belief that our stock price would be substantially higher if all this was known.
Gary
I'm hoping the planned Phase 1 for the sublingual tablet will be done with people who have conditions that should benefit from it. I know a Phase 2 is planned for the psoriasis cream, and that should tell a lot. I know we've already done more than a lot of companies selling products have.
The reason I've stressed the fact that planned trials should be put in the clinical trials database is because it would answer practically all questions about the trials. It may take some additional effort to do it, but I suspect that virtually everything that's revealed in the clinical trials database can be found in what's done with the IRB as the trial's being designed. I'm of the belief that our stock price would be substantially higher if all this was known.
Gary
(1)
(0)
